Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
240
Trial Sponsor
Clinical Trial Start Date
March 26, 2015
0Primary Completion Date
November 9, 2017
0Study Completion Date
September 26, 2018
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Biological0
Intervention Name
enoblituzumab plus ipilimumab0
Interventional Trial Phase
Phase 10
Participating Facility
Official Name
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers0
Last Updated
February 8, 2022
0Allocation Type
NA0
Intervention Model
Single Group Assignment0
Masking Type
None (Open Label)0
Study summary
The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Yervoy (ipilimumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC) and other B7-H3 expressing cancers. The study will also evaluate what is the best dose of enoblituzumab to use when given with ipilimumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of enoblituzumab in combination with ipilimumab.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
